Johnson & Johnson (NYSE:JNJ) Stake Lifted by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 6.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,807 shares of the company’s stock after purchasing an additional 589 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Johnson & Johnson were worth $1,626,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Trust Co. of Toledo NA OH grew its stake in shares of Johnson & Johnson by 2.4% in the first quarter. Trust Co. of Toledo NA OH now owns 45,280 shares of the company’s stock worth $7,509,000 after purchasing an additional 1,072 shares in the last quarter. Optas LLC grew its stake in shares of Johnson & Johnson by 26.8% in the first quarter. Optas LLC now owns 6,183 shares of the company’s stock worth $1,025,000 after purchasing an additional 1,306 shares in the last quarter. D Orazio & Associates Inc. grew its stake in shares of Johnson & Johnson by 54.3% in the first quarter. D Orazio & Associates Inc. now owns 9,267 shares of the company’s stock worth $1,537,000 after purchasing an additional 3,262 shares in the last quarter. Hengehold Capital Management LLC grew its stake in shares of Johnson & Johnson by 4.2% in the first quarter. Hengehold Capital Management LLC now owns 26,046 shares of the company’s stock worth $4,319,000 after purchasing an additional 1,044 shares in the last quarter. Finally, Brighton Jones LLC grew its stake in shares of Johnson & Johnson by 4.0% in the first quarter. Brighton Jones LLC now owns 53,944 shares of the company’s stock worth $8,946,000 after purchasing an additional 2,068 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on JNJ. Raymond James decreased their price target on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 5th. Wall Street Zen cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Finally, Bank of America decreased their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Stock Up 0.2%

Shares of Johnson & Johnson stock opened at $156.90 on Monday. The stock has a 50-day moving average price of $153.84 and a 200 day moving average price of $153.70. The company has a market cap of $377.52 billion, a P/E ratio of 23.59, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a $1.30 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.31%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.